ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer

Oncotarget

Volumn 7, Issue 13, 2016, Pages 15811-15827

  Schlienger, Sabrina ^a   Campbell, Shirley ^a   Pasquin, Sarah ^a   Gaboury, Louis ^b   Claing, Audrey ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

ADP ribosylation factor (ARF); Breast cancer; Emt; Invasion; Metastasis

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 1; BETA CATENIN; RAS PROTEIN; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CELL ADHESION; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADP-RIBOSYLATION FACTOR 1; ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, SCID; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84971624335     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7515     Document Type: Article

References (50)

1. Burness ML, Grushko TA and Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer journal. 2010; 16:23-32.
2. Guillamo JS, de Bouard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E and Peschanski M. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clinical cancer research. 2009; 15:3697-3704.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research. 2004; 10:5367-5374.
4. Parada LF, Tabin CJ, Shih C and Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982; 297:474-478.
5. Der CJ, Krontiris TG and Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79:3637-3640.
6. Santos E, Tronick SR, Aaronson SA, Pulciani S and Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB-and Harvey-MSV transforming genes. Nature. 1982; 298:343-347.
7. D'Souza-Schorey C and Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nature reviews Molecular cell biology. 2006; 7:347-358.
8. Boulay PL, Cotton M, Melancon P and Claing A. ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. The Journal of biological chemistry. 2008; 283:36425-36434.
9. Boulay PL, Schlienger S, Lewis-Saravalli S, Vitale N, Ferbeyre G and Claing A. ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein. Oncogene. 2011; 30:3846-3861.
10. Schlienger S, Campbell S and Claing A. ARF1 regulates the Rho/MLC pathway to control EGF-dependent breast cancer cell invasion. Molecular biology of the cell. 2014; 25:17-29.
11. Schlienger S, Ramirez RA and Claing A. ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions. Cellular signalling. 2015; 27:403-415.
12. Hashimoto S, Onodera Y, Hashimoto A, Tanaka M, Hamaguchi M, Yamada A and Sabe H. Requirement for Arf6 in breast cancer invasive activities. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:6647-6652.
13. Kahn RA, Randazzo P, Serafini T, Weiss O, Rulka C, Clark J, Amherdt M, Roller P, Orci L and Rothman JE. The amino terminus of ADP-ribosylation factor (ARF) is a critical determinant of ARF activities and is a potent and specific inhibitor of protein transport. The Journal of biological chemistry. 1992; 267:13039-13046.
14. Galas MC, Helms JB, Vitale N, Thierse D, Aunis D and Bader MF. Regulated exocytosis in chromaffin cells. A potential role for a secretory granule-associated ARF6 protein. The Journal of biological chemistry. 1997; 272:2788-2793.
15. Cohen LA, Honda A, Varnai P, Brown FD, Balla T and Donaldson JG. Active Arf6 recruits ARNO/cytohesin GEFs to the PM by binding their PH domains. Molecular biology of the cell. 2007; 18:2244-2253.
16. Mitchell R, Robertson DN, Holland PJ, Collins D, Lutz EM and Johnson MS. ADP-ribosylation factor-dependent phospholipase D activation by the M3 muscarinic receptor. The Journal of biological chemistry. 2003; 278:33818-33830.
17. Morishige M, Hashimoto S, Ogawa E, Toda Y, Kotani H, Hirose M, Wei S, Hashimoto A, Yamada A, Yano H, Mazaki Y, Kodama H, Nio Y, Manabe T, Wada H, Kobayashi H, et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nature cell biology. 2008; 10:85-92.
18. Tsai MM, Lin PY, Cheng WL, Tsai CY, Chi HC, Chen CY, Tseng YH, Cheng YF, Chen CD, Liang Y, Liao CJ, Wu SM, Lin YH, Chung IH, Wang CS and Lin KH. Overexpression of ADP-ribosylation factor 1 in human gastric carcinoma and its clinicopathological significance. Cancer science. 2012; 103:1136-1144.
19. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A and Kandpal RP. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene. 2006; 25:2328-2338.
20. Peinado H, Olmeda D and Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature reviews Cancer. 2007; 7:415-428.
21. de Jong JS, van Diest PJ, Michalides RJ and Baak JP. Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas. Molecular pathology. 1999; 52:78-83.
22. Mao Y, Keller ET, Garfield DH, Shen K and Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer metastasis reviews. 2013; 32:303-315.
23. Poondru S, Parchment RE, Purohit V, LoRusso P, Horwitz JP, Hazeldine ST, Polin L, Corbett T and Jasti BR. Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30. Investigational new drugs. 2002; 20:23-33.
24. Williams CS, Watson AJ, Sheng H, Helou R, Shao J and DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer research. 2000; 60:6045-6051.
25. Onodera Y, Hashimoto S, Hashimoto A, Morishige M, Mazaki Y, Yamada A, Ogawa E, Adachi M, Sakurai T, Manabe T, Wada H, Matsuura N and Sabe H. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. The EMBO journal. 2005; 24:963-973.
26. Eades G, Wolfson B, Zhang Y, Li Q, Yao Y and Zhou Q. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2015; 13:330-338.
27. Marchesin V, Castro-Castro A, Lodillinsky C, Castagnino A, Cyrta J, Bonsang-Kitzis H, Fuhrmann L, Irondelle M, Infante E, Montagnac G, Reyal F, Vincent-Salomon A and Chavrier P. ARF6-JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion. The Journal of cell biology. 2015; 211:339-358.
28. Lee MH, Koria P, Qu J and Andreadis ST. JNK phosphorylates beta-catenin and regulates adherens junctions. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2009; 23:3874-3883.
29. Maher MT, Mo R, Flozak AS, Peled ON and Gottardi CJ. Beta-catenin phosphorylated at serine 45 is spatially uncoupled from beta-catenin phosphorylated in the GSK3 domain: implications for signaling. PloS one. 2010; 5:e10184.
30. Sadot E, Conacci-Sorrell M, Zhurinsky J, Shnizer D, Lando Z, Zharhary D, Kam Z, Ben-Ze'ev A and Geiger B. Regulation of S33/S37 phosphorylated beta-catenin in normal and transformed cells. Journal of cell science. 2002; 115:2771-2780.
31. Faux MC, Coates JL, Kershaw NJ, Layton MJ and Burgess AW. Independent interactions of phosphorylated beta-catenin with E-cadherin at cell-cell contacts and APC at cell protrusions. PloS one. 2010; 5:e14127.
32. Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S and Lu X. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell death and differentiation. 2013; 20:525-534.
33. Gimond C, van Der Flier A, van Delft S, Brakebusch C, Kuikman I, Collard JG, Fassler R and Sonnenberg A. Induction of cell scattering by expression of beta1 integrins in beta1-deficient epithelial cells requires activation of members of the rho family of GTPases and downregulation of cadherin and catenin function. The Journal of cell biology. 1999; 147:1325-1340.
34. Price LS and Collard JG. Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Seminars in cancer biology. 2001; 11:167-173.
35. Radisky ES and Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. Journal of mammary gland biology and neoplasia. 2010; 15:201-212.
36. Hauck CR, Hsia DA, Ilic D and Schlaepfer DD. v-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion. The Journal of biological chemistry. 2002; 277:12487-12490.
37. Zhang Y, Thant AA, Hiraiwa Y, Naito Y, Sein TT, Sohara Y, Matsuda S and Hamaguchi M. A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QG90. Biochem Biophys Res Commun. 2002; 290:1123-1127.
38. Lim Y, Han I, Jeon J, Park H, Bahk YY and Oh ES. Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for Ras transformation of fibroblasts. The Journal of biological chemistry. 2004; 279:29060-29065.
39. Yousef EM, Tahir MR, St-Pierre Y and Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC cancer. 2014; 14:609.
40. Bocker W. [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 2002; 86:116-119.
41. Caldarella A, Puliti D, Crocetti E, Bianchi S, Vezzosi V, Apicella P, Biancalani M, Giannini A, Urso C, Zolfanelli F and Paci E. Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening. Journal of cancer research and clinical oncology. 2013; 139:181-185.
42. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology. 2013; 31:3997-4013.
43. Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, Xie YQ, Shao YF and Zhao XH. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World journal of gastroenterology. 2004; 10:1466-1470.
44. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM and Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:13057-13062.
45. Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro G, Yao YM, Lengauer C, Sellers WR and Benson JD. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell cycle. 2009; 8:498-504.
46. Liao YC, Ruan JW, Lua I, Li MH, Chen WL, Wang JR, Kao RH and Chen JH. Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene. 2012; 31:3086-3097.
47. Cawthorne C, Swindell R, Stratford IJ, Dive C and Welman A. Comparison of doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. Journal of biomolecular techniques. 2007; 18:120-123.
48. Tomayko MM and Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer chemotherapy and pharmacology. 1989; 24:148-154.
49. Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, Yuan G, Zhang H, Yu M, Hu M, Shen B and Guo N. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC cancer. 2007; 7:145.
50. Cotton M, Boulay PL, Houndolo T, Vitale N, Pitcher JA and Claing A. Endogenous ARF6 interacts with Rac1 upon angiotensin II stimulation to regulate membrane ruffling and cell migration. Molecular biology of the cell. 2007; 18:501-511.